Literature DB >> 26865392

Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study.

I Duran1, M G Fink2, A Bahl3, H Hoefeler4, A Mahmood5, D Lüftner6, H Ghazal7, R Wei8, K C Chung9, G Hechmati10, J Green11, C Atchison9.   

Abstract

Skeletal-related events (SREs) including spinal cord compression, pathologic fracture, and radiation or surgery to bone, occur frequently due to bone metastases in advanced cancer. This analysis of a multicentre, observational study was designed to describe cross-regional differences in health resource utilisation (HRU) of SREs in Western Europe and the US. Patients with bone metastases due to breast, lung or prostate cancer, or multiple myeloma who had experienced a SRE within the past 97 days were enrolled. Investigators recorded HRU associated with SREs, including hospitalisation and length of stay (LOS), outpatient visits, procedures and bisphosphonate use. This subanalysis includes 668 patients with solid tumours (US, n = 190 with 354 SREs; EU, n = 478 with 893 SREs). The rate of SREs associated with hospitalisation(s) was higher in the EU vs. the US (30% vs. 15%, P < 0.001) and LOS was longer in the EU [mean (SD) days/SRE: 19.87 (17.31) vs. 10.61 (9.39)]. However, the US was associated with higher rate of SREs with outpatient visits than the EU (88% vs. 74%, P < 0.0001) and more procedures [mean (SD)/SRE: 11.26 (7.94) vs. 6.91 (6.48)]. Bisphosphonates were less often used in the EU (65% vs. 76% of US, P = 0.0033). In patients experiencing SREs due to bone metastases, HRU patterns reflect regional diversity with a substantial burden in both regions.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  Cancer; European; management; palliative care; symptoms

Mesh:

Substances:

Year:  2016        PMID: 26865392     DOI: 10.1111/ecc.12452

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  6 in total

1.  Evaluating factors affecting length of hospital stay in patients with metastatic bone tumors.

Authors:  Nicole Hughes; Jacob Birlingmair; Jordan Baker; Grace Tideman; Kyle Sweeney
Journal:  J Orthop       Date:  2022-01-13

2.  Prevalence and risk of skeletal complications and use of radiation therapy in elderly women diagnosed with metastatic breast cancer.

Authors:  Arif Hussain; Candice Yong; Katherine H R Tkaczuk; Yi Qian; Jorge Arellano; C Daniel Mullins; Eberechukwu Onukwugha
Journal:  PLoS One       Date:  2018-03-01       Impact factor: 3.752

3.  Beta tricalcium phosphate, either alone or in combination with antimicrobial photodynamic therapy or doxycycline, prevents medication-related osteonecrosis of the jaw.

Authors:  Henrique Hadad; Laís Kawamata de Jesus; Ana Flávia Piquera Santos; Henrique Rinaldi Matheus; Letícia Gabriella de Souza Rodrigues; Pier Paolo Poli; Elcio Marcantonio Junior; Fernando Pozzi Semeghini Guastaldi; Carlo Maiorana; Juliano Milanezi de Almeida; Roberta Okamoto; Francisley Ávila Souza
Journal:  Sci Rep       Date:  2022-10-03       Impact factor: 4.996

4.  Evaluation of results and costs of high precision radiotherapy (VMAT) compared with conventional radiotherapy (3D) in the treatment of cancer patients with spinal cord compression of metastatic origin.

Authors:  Jon Cacicedo; Elisa Gómez Inhiesto; Maria Teresa Acaiturri Ayesta; Iker Ustarroz; Dirk Rades
Journal:  Rep Pract Oncol Radiother       Date:  2022-09-19

Review 5.  Metastasis-directed therapy for oligometastasis and beyond.

Authors:  Thomas H Beckham; T Jonathan Yang; Daniel Gomez; C Jillian Tsai
Journal:  Br J Cancer       Date:  2020-11-18       Impact factor: 7.640

6.  Early palliative radiation versus observation for high-risk asymptomatic or minimally symptomatic bone metastases: study protocol for a randomized controlled trial.

Authors:  Daniel B Rosen; Cory D Benjamin; Joanna C Yang; Connor Doyle; Zhigang Zhang; Chris A Barker; Max Vaynrub; T Jonathan Yang; Erin F Gillespie
Journal:  BMC Cancer       Date:  2020-11-17       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.